Veracyte (VCYT) Could Be 16% Undervalued On Decipher And Prosigna Progress

Veracyte (VCYT) is back in focus after two cancer diagnostics updates, including Level 1B predictive evidence for its Decipher prostate test and new MolDX reimbursement coverage for the Prosigna breast cancer assay.

Veracyte’s recent clinical updates have arrived alongside a sharp move in the shares, with the 1-day and 7-day share price returns of 4.32% and 12.26% suggesting short-term momentum after a 90-day share price decline of 9.75% and a stronger 1-year total shareholder return of 41.24%.

Scan other cancer diagnostics players that are showing similar clinical traction and pricing momentum with our curated 34 healthcare AI stocks list.

Veracyte now has a richer story, with fresh prostate and breast cancer data on one side and a share price that has already moved on the news on the other. How does that balance look in terms of valuation today?

Most Popular Narrative: 16% Undervalued

Veracyte’s most followed valuation storyline pegs fair value at $59.73 versus the latest close at $50.28, so the current pricing gap leans in favor of that narrative and puts recent prostate and breast test news in a wider earnings and margin context.

Pipeline momentum with five major product launches and a pivotal clinical study (OPTIMA) completing in the next 18 months positions Veracyte to further diversify revenue, drive cross-selling, penetrate new markets (for example, MRD in bladder cancer and Prosigna for breast cancer), and significantly expand addressable markets, supporting long-term topline acceleration.

See why 13 investors see Veracyte as 16% undervalued.

Result: Fair Value of $59.73 (UNDERVALUED)

Still, the Veracyte story leans heavily on Decipher and Afirma, so any reimbursement pushback or slower uptake for newer tests could quickly challenge that 16% undervalued case.

Find out about the key risks to this Veracyte narrative.

Another View: Veracyte On Earnings Multiples

The SWS DCF work suggests Veracyte is undervalued, yet the earnings multiple paints a different picture. VCYT trades on a P/E of 35.3x, compared with a fair ratio of 17.8x, the US Biotechs average of 18.6x and a peer average of 35.2x. That points to rich pricing. Which signal matters more for you?

To see how that earnings multiple could move closer to the fair ratio and what that might mean for future upside or downside risk, See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

Mixed messages in the Veracyte story so far, or a balanced risk and reward profile that needs fresh eyes today. Act while the data is current and weigh both sides for yourself with 3 key rewards and 1 important warning sign

Looking for more investment ideas beyond Veracyte?

If Veracyte has sharpened your focus, do not stop here. Broaden your watchlist with fresh ideas that match your style before other investors get there first.

• Target potential mispricing by scanning a focused universe of stocks that our models flag as promising using the 29 high quality undervalued stocks.
• Prioritize resilience by filtering for businesses with strong finances and robust balance sheets with the list of solid balance sheet and fundamentals (24 results).
• Go hunting for under-the-radar opportunities by reviewing the 21 high quality undiscovered gems that combine quality fundamentals with limited current attention.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com